BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Core Insights - BeyondSpring Inc. is hosting a Research and Development Day on May 15, 2024, to discuss unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic [1] - Key Opinion Leaders will present on Plinabulin's history, its immunomodulatory activity, and the needs following immune-checkpoint-inhibitor failure [1] - The event will also include updates on SEED Therapeutics, BeyondSpring's subsidiary focused on drug discovery [1] Company Overview - BeyondSpring is a clinical-stage global biopharmaceutical company dedicated to developing innovative cancer therapies [6] - The company is advancing Plinabulin as a direct anti-cancer agent and for preventing chemotherapy-induced neutropenia [6] - BeyondSpring's pipeline includes three preclinical immuno-oncology assets and a collaboration with Eli Lilly through its subsidiary SEED Therapeutics [6][7] Key Opinion Leaders - Dr. Trevor M. Feinstein is the Director of Research at Piedmont Fayette Hospital, involved in clinical trials for cancer therapies [3] - Dr. Alberto Chiappori is a senior member of the Thoracic Oncology Program at Moffitt Cancer Center, actively participating in various oncology societies [4] - Dr. Steven Lin is a Professor at MD Anderson Cancer Center, focusing on thoracic malignancies and overseeing clinical trials involving immunotherapy and radiotherapy [5]